US EditionASCO25: Focus V fails to show superiority over bevacizumab in first-line metastatic CRC
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
ASCO25: Focus V fails to show superiority over bevacizumab in first-line metastatic CRC
Focus V has shown limited PFS benefit, a high incidence of AEs, and no demonstrated improvement in overall survival.The post ASCO25: Focus V fails to show superiority over bevacizumab in first-line metastatic CRC appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage